Cowen Research Themes 2021 has been published. Click here to learn about the year's key investment themes. >

$75 Million

Avrobio

Follow-on Offering

Bookrunner, November 2020

AVROBIO, Inc. is a clinical-stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The Company’s gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is defective in the target disease. The Company has assembled a leading platform of potentially curative ex vivo lentiviral-based gene therapies and is currently focused on a group of rare genetic lysosomal storage diseases with well understood biology and identified patient populations. AVROBIO’s lead asset, AVR-RD-01 is currently being studied in two ongoing clinical trials in Fabry disease.

More Like This

Jan 2021
$144 Million
DermTech logo

Follow-on Offering

Lead Left Bookrunner

View Details
Jan 2021
$225 Million

Follow-on Offering

Bookrunner

View Details
Jan 2021
$144 Million

Follow-on Offering

Bookrunner

View Details